Literature DB >> 26733340

Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Kazuhiro Kitajima1, Yasuo Miyoshi2.   

Abstract

Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) is a useful tool for acquisition of both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session, and has opened a new field in clinical oncologic imaging. FDG-PET/CT has been used successfully for the diagnosis, initial staging, restaging, early treatment response assessment, evaluation of metastatic disease response, and prognostication of breast cancer as well as various malignant tumors. We herein review the current place and role of FDG-PET/CT in the management of breast cancer, focusing on its usefulness and limitations in the imaging of these patients.

Entities:  

Keywords:  Breast cancer; Fluorodeoxyglucose (FDG); Positron emission tomography/computed tomography (PET/CT); Restaging; Staging

Mesh：

Substances：

Year:  2016        PMID： 26733340     DOI： 10.1007/s11604-015-0516-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN： 1867-1071            Impact factor:   2.374


  100 in total

1.  The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.

Authors:  David Groheux; Sylvie Giacchetti; Marc Espié; Laetitia Vercellino; Anne-Sophie Hamy; Marc Delord; Nathalie Berenger; Marie-Elisabeth Toubert; Jean-Louis Misset; Elif Hindié
Journal:  J Nucl Med       Date:  2011-08-30       Impact factor: 10.057

2.  Monitoring primary breast cancer throughout chemotherapy using FDG-PET.

Authors:  Garry M McDermott; Andrew Welch; Roger T Staff; Fiona J Gilbert; Lutz Schweiger; Scott I K Semple; Tim A D Smith; Andrew W Hutcheon; Iain D Miller; Ian C Smith; Steven D Heys
Journal:  Breast Cancer Res Treat       Date:  2006-08-09       Impact factor: 4.872

3.  Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

Authors:  David Groheux; Elif Hindié; Sylvie Giacchetti; Anne-Sophie Hamy; Frederique Berger; Pascal Merlet; Anne de Roquancourt; Patricia de Cremoux; Michel Marty; Mathieu Hatt; Marc Espié
Journal:  Eur J Cancer       Date:  2014-05-16       Impact factor: 9.162

4.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

5.  Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.

Authors:  Kathleen I Pritchard; Jim A Julian; Claire M B Holloway; David McCready; Karen Yvonne Gulenchyn; Ralph George; Nicole Hodgson; Peter Lovrics; Francisco Perera; Leela Elavathil; Frances P O'Malley; Nancy Down; Audley Bodurtha; Wendy Shelley; Mark N Levine
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

Review 6.  Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response.

Authors:  Christoph I Lee; Laura S Gold; Heidi D Nelson; Roger Chou; Scott D Ramsey; Sean D Sullivan
Journal:  Breast       Date:  2014-12-03       Impact factor: 4.380

7.  Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Authors:  David Groheux; Mathieu Hatt; Elif Hindié; Sylvie Giacchetti; Patricia de Cremoux; Jacqueline Lehmann-Che; Antoine Martineau; Michel Marty; Caroline Cuvier; Catherine Cheze-Le Rest; Anne de Roquancourt; Dimitris Visvikis; Marc Espié
Journal:  Cancer       Date:  2013-03-15       Impact factor: 6.860

8.  Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis.

Authors:  Carmelo Caldarella; Giorgio Treglia; Alessandro Giordano
Journal:  Clin Breast Cancer       Date:  2013-12-27       Impact factor: 3.225

9.  Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.

Authors:  Jeryong Kim; Jinsun Lee; Eilsung Chang; Seongmin Kim; Kwangsun Suh; Jiyoung Sul; Insang Song; Yonghoon Kim; Chuljoo Lee
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

10.  HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

Authors:  Olivier Humbert; Alexandre Cochet; Jean-Marc Riedinger; Alina Berriolo-Riedinger; Laurent Arnould; Bruno Coudert; Isabelle Desmoulins; Michel Toubeau; Inna Dygai-Cochet; Séverine Guiu; Charles Coutant; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-20       Impact factor: 9.236
View more
  5 in total

1.  18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT.

Authors:  Cheng Liu; Chengcheng Gong; Shuai Liu; Yingjian Zhang; Yongping Zhang; Xiaoping Xu; Huiyu Yuan; Biyun Wang; Zhongyi Yang
Journal:  Oncologist       Date:  2019-07-23

2.  Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi; Toshiko Yamano; Soichi Odawara; Tomoko Higuchi; Koichiro Yamakado
Journal:  Nagoya J Med Sci       Date:  2018-05       Impact factor: 1.131

3.  Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.

Authors:  Michele Balma; Virginia Liberini; Manuela Racca; Riccardo Laudicella; Matteo Bauckneht; Ambra Buschiazzo; Daniele Giovanni Nicolotti; Simona Peano; Andrea Bianchi; Giovanni Albano; Natale Quartuccio; Ronan Abgral; Silvia Daniela Morbelli; Calogero D'Alessandria; Enzo Terreno; Martin William Huellner; Alberto Papaleo; Désirée Deandreis
Journal:  Front Med (Lausanne)       Date:  2022-04-12

4.  Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.

Authors:  Inga B Fricke; Raquel De Souza; Lais Costa Ayub; Giulio Francia; Robert Kerbel; David A Jaffray; Jinzi Zheng
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

5.  Retrospective Analysis of Patients with Synchronous Primary Breast and Thyroid Carcinoma.

Authors:  İlker Murat Arer; Hakan Yabanoğlu; Murat Kuş; Aydıncan Akdur; Tevfik Avcı
Journal:  Eur J Breast Health       Date:  2018-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.